MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).
P. A. Ellis
Consultant or Advisory Role - Roche/Genentech (U)
Honoraria - Roche/Genentech
C. H. Barrios
Consultant or Advisory Role - Roche
Honoraria - Roche
Y. Im
No relevant relationships to disclose
M. Patre
Employment or Leadership Position - Roche
F. Branle
Employment or Leadership Position - Roche
Other Remuneration - Sanofi
E. A. Perez
Research Funding - Genentech; GlaxoSmithKline